...assays for Acea's xCELLigence system. The new assays will use Vivo's HuBiogel technology, a human-derived biomatrix...

...Pegasus' marketed products OrthAdapt Bioimplant, a type I collagen scaffold for tissue damage; and Unite Biomatrix...

...German and Brazilian STEALTH trial in 120 patients, angiographic analysis at 6 months showed the BioMatrix...
...compared to the bare metal stent group (3.9% vs. 7.7%, p=0.4). The analysis also showed Biomatrix...
...p<0.001). Intravascular ultrasound (IVUS) analysis showed the percent neointimal volume was significantly lower in the Biomatrix...

...receive marketing approval in Japan next year. WYE obtained rights to Synvisc in 1997 from Biomatrix...

...markets the drug in certain countries. In 1997, WYE gained rights to the compound from Biomatrix...

...fair market value, which they put at $1.5-$2 billion. Riggs is the former president of Biomatrix...

...$2 billion. GENZ said the suit is without merit. Riggs is the former president of Biomatrix...
...maintain a tracking stock structure that would "protect the holders' interest in the value of Biomatrix's...

...$1.5-$2 billion. GENZ said the suit is without merit. Riggs is the former president of Biomatrix...

...rose 32% to $26.4 million from the first quarter of 2002. Synvisc was developed by Biomatrix...
...March 2000 to form GZBX (see BioCentury, March 13, 2000) . That deal initially valued Biomatrix...
...ever since. GENZ estimates it spent about $476 million in cash and stock to acquire Biomatrix...

...exclusive license in the territory for two years, markets the products under its Hyalogen label. Biomatrix Inc....